Ajanta Pharma spurts to record high after healthy Q4 earnings

Ajanta Pharma spurted 10.35% to Rs 1078.80 at 14:45 IST on BSE after profit after tax jumped 159% to Rs 70 crore on 25% growth in revenue from operations to Rs 311 crore in Q4 March 2014 over Q4 March 2013.

The Q4 result was announced during trading hours today, 5 May 2014.

Meanwhile, the S&P BSE Sensex was up 116.91 points or 0.52% at 22,520.80.

The stock spurted on heavy volumes. On BSE, so far 3.57 lakh shares were traded in the counter as against average daily volume of 10,416 shares in the past one quarter.

The stock hit a high of Rs 1,138.60 so far during the day, which is also its record high for the counter. The stock hit a low of Rs 984.05 so far during the day. The stock had hit a 52-week low of Rs 475.34 on 28 August 2013.

The stock had underperformed the market over the past one month till 2 May 2014, sliding 1.7% compared with the Sensex's 0.65% fall. The scrip had also underperformed the market in past one quarter, advancing 3.65% as against Sensex's 9.21% rise.

The small-cap company has equity capital of Rs 17.58 crore. Face value per share is Rs 5.

Ajanta Pharma's EBITDA (earnings before interest, taxation, depreciation and amortization) surged 63% to Rs 112 crore in Q4 March 2014 over Q4 March 2013.

Exports contributed 66% of the total operating income in Q4 March 2014, Ajanta Pharma said.

Ajanta Pharma's profit after tax surged 118% to Rs 221 crore on 32% growth in revenue from operations to Rs 1110 crore in the year ended 31 March 2014 (FY 2014) over the year ended 31 March 2013 (FY 2013).

EBITDA jumped 65% to Rs 346 crore in FY 2014 over FY 2013.

Exports contributed 63% of the total operating income for FY 2014, Ajanta Pharma said.

On consolidated basis, Ajanta Pharma's profit after tax jumped 109% to Rs 234 crore on 30% growth in revenue from operations to Rs 1208 crore in FY 2014 over FY 2013.

EBITDA jumped 64% to Rs 369 crore in FY 2014 over FY 2013.

Mr. Yogesh Agrawal, MD, Ajanta Pharma said, "We are pleased with the execution of our strategy during the year which is reflected in healthy results. All our geographies have performed inline with our expectations. Our India speciality business continues to post robust growth much above the industry growth. We continue to build branded generic business in select overseas markets and lay foundation for sustained growth in coming years".

Ajanta Pharma's board of directors at its meeting held today, 5 May 2014, recommended dividend of Rs 10 per share, subject to approval of shareholders at the ensuing Annual General Meeting to be held in 2014.

Ajanta Pharma - a speciality pharmaceutical formulation company has leading brands in therapeutic segments of ophthalmology, dermatology, cardiology and pain management.

Powered by Capital Market - Live News